VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2026 Earnings Call Transcript November 13, 2025
VistaGen Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.54 EPS, expectations were $-0.51.
Operator: Good day, everyone. Thank you for standing by. Welcome to the Vistagen Therapeutics’ Fiscal Year 2026 Second Quarter Corporate Update Conference Call and Webcast. Please note that today’s call is being recorded. At this time, I’d like to turn the call over to your host, Mark...
